ArticleDisease markers2015
Overexpression of Growth-Related Oncogene-β Is Associated with Tumorigenesis, Metastasis, and Poor Prognosis in Ovarian Cancer.
Article in Disease markers, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 7 citations in OpenAlex.
- MicroRNA‑27a‑3p regulates the proliferation and chemotaxis of pulmonary macrophages in non‑small cell lung carcinoma tissues through CXCL2.Oncology letters · 2023Article
- CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer.Journal of ovarian research · 2021Article
- Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer.Journal of Cancer · 2021Review
- The prognostic implications of growth-related gene product β in laryngeal squamous cell carcinoma.Oncology letters · 2017Article
- Collaboration of cancer-associated fibroblasts and tumour-associated macrophages for neuroblastoma development.The Journal of pathology · 2016Article
- Small molecule inhibitor of c-Met (PHA665752) suppresses the growth of ovarian cancer cells and reverses cisplatin resistance.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGrowth-related oncogene- (GRO-) β is a member of the CXC chemokine family, which may mediate various functions, such as attracting neutrophils to sites of inflammation, regulating angiogenesis, and participating in tumorigenesis and progression. However, the expression of GRO-β in ovarian cancer and its relationship to the clinical characteristics of this disease remain poorly understood.
methodsIn this study, immunohistochemical analysis using tissue microarray (TMA) was employed to evaluate the expression of GRO-β in ovarian cancer and to contrast expression with normal ovarian epithelial cells and oviduct epithelial cells. Next, we observed the correlation between GRO-β expression and clinicopathological features of ovarian cancer as well as patient outcome.
resultsHigh GRO-β cytoplasmic expression was observed in 55.15% of patients with ovarian cancer, which was related to lymph node or other metastases (P < 0.001), ascites (P = 0.027), and International Federation of Obstetricians and Gynaecologists (FIGO) stage (P = 0.032). Kaplan-Meier survival and Cox regression analysis revealed that high GRO-β expression (P = 0.002) and high CA19-9 level (P = 0.003) were independent prognostic indicators of poor outcome in ovarian cancer.
conclusionsOverall, high GRO-β expression correlates with poor prognosis and contributes to ovarian cancer tumorigenesis and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.